Secondary malignancies and survival of FCR‐treated patients with chronic lymphocytic leukemia in Central Europe

This is the first large‐scale cross‐country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central Eu...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2023-01, Vol.12 (2), p.1961-1971
Main Authors: Kósa, Fruzsina, Nečasová, Tereza, Špaček, Martin, Giannopoulos, Krzysztof, Hus, Iwona, Jurková, Tereza, Koriťáková, Eva, Chrápavá, Marika, Nováčková, Martina, Katinová, Ivana, Krejčí, Denisa, Jujka, Adam, Mátrai, Zoltán, Vályi‐Nagy, István, Robak, Tadeusz, Doubek, Michael
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cancer
Chemotherapy
Chronic lymphocytic leukemia
CLL population
Codes
Cyclophosphamide - therapeutic use
Data collection
Decision making
Diagnosis
Disease-Free Survival
Drugs
Europe - epidemiology
FCR therapy
Hospitals
Humans
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology
Lymphoma
Male
Malignancy
Medical prognosis
Melanoma
Patients
Registration
Retrospective Studies
Risk factors
Rituximab - therapeutic use
secondary malignancy
Statistical analysis
Survival
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This is the first large‐scale cross‐country analysis of patients with chronic lymphocytic leukemia (CLL) aimed to evaluate the incidence, types, and key prognostic factors of secondary malignancies, and to assess the impact on overall survival based on retrospective claims data from three Central European countries. We analyzed 25,814 newly diagnosed CLL patients from Czechia, Hungary, and Poland; 10,312 (39.9%) patients were treated for CLL in study periods between 2004 and 2016. Out of the treated patients, 1986 (19.3%) received the FCR therapy in the first line and 779 (7.6%) received FCR in subsequent lines. We observed that 33.7% of treated patients developed secondary malignancies during the study. Based on country estimates, the probability to develop a secondary malignancy within 4 years since starting the first‐line FCR therapy ranged between 28.0% and 36.8%. We found the age at diagnosis, male gender, any malignancy prior to the CLL diagnosis, and the CLL treatment to be the key risk factors for developing secondary malignancies. Specifically, the FCR therapy was a statistically significant (p 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.5033